Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

HCG and LGD-4033 Interaction: Monitor | Peptide Database

Compound Profiles HCG Human Chorionic Gonadotropin | LH Receptor Agonist Binds to LH receptors on Leydig cells in testes, stimulating testosterone production with a half-life of 24-36 hours, peak levels 6-12 hours post-injection, and 40-50% bioavailability via

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

HCG

Human Chorionic Gonadotropin | LH Receptor Agonist

Binds to LH receptors on Leydig cells in testes, stimulating testosterone production with a half-life of 24-36 hours, peak levels 6-12 hours post-injection, and 40-50% bioavailability via SubQ or IM routes..

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take HCG with LGD-4033?

Yes, but with caution. Both HCG and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is HCG and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic, teratogenic. Monitor accordingly.

What are the interactions between HCG and LGD-4033?

Both HCG and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time HCG and LGD-4033?

HCG has a half-life of 24-36 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research. Demonstrated effectiveness against breast cancer cell lines. Induces necrosis of K-562 leukemia cells through HDM-2 binding. Shows selective targeting of melanoma cells. Most effective against cancers with high membrane HDM-2 expression. Model compound for studying cancer-selective therapies.

Source: peptide-db.com ↗

Research Indications

Primary FDA-approved indication for anemia secondary to chronic kidney disease. FDA-approved for treating anemia in cancer patients receiving chemotherapy. Used to reduce need for blood transfusions in certain surgical settings. Increases oxygen delivery to muscles, improving endurance capacity. Banned by WADA. May accelerate adaptation to high altitude by increasing red blood cell mass.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Direct brain access via olfactory nerves with rapid onset and proven efficacy. Cognitive enhancement 600mcg 1x daily Intranasal spray Mental fatigue resistance 800mcg Memory enhancement 2x daily Neuroprotection 1200mcg

Source: peptide-db.com ↗
Side effects

Common Side Effects

Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6) Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase) HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials) Headaches (most common in the first 1-2 weeks, usually transient) Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle) Reduced libido (related to HPG axis suppression, severity varies by dose and individual)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides